Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Gilead Sciences, Inc., Novartis Pharmaceuticals Corporation, and Takeda Oncology.

Exploring Current and Emerging Data Sets to Move Treatment of Higher-Risk MDS Forward: A Focus on Novel Targets and Treatment Approaches

Release Date: July 20, 2021
Expiration Date: July 20, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in myelodysplastic syndromes (MDS). In this educational program these experts review the latest data regarding risk stratification and emerging treatment approaches for managing patients with higher-risk MDS. Using a case-based format, the panel discusses clinical implications, shares their perspectives and best practices, and forecasts applications of key clinical challenges and questions regarding the clinical management of higher-risk MDS including risk stratification methods, novel biomarkers, progression to acute myeloid leukemia, assessing transplant eligibility, selecting subsequent-line therapy, emerging combination treatment approaches, and managing adverse events for patients with higher-risk MDS.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Gilead Sciences, Inc., Novartis Pharmaceuticals Corporation, and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.


Target Audience

This educational program is directed toward the ASCO audience, including hematologists and medical oncologists interested in the treatment of HR-MDS. Other allied healthcare professionals, including pathologists, nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with MDS are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the criteria for MDS diagnosis, and guidelines for risk stratification among these patients
  • Determine the impact of risk assessment on treatment selection in patients with higher-risk MDS
  • Assess the efficacy and safety profiles for current and emerging agents/combinations in patients with higher-risk MDS
  • Evaluate updated clinical evidence from landmark trials in the context of current treatment algorithms for patients with higher-risk MDS

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Mikkael A. Sekeres, MD
Mikkael A. Sekeres, MD
Chief, Division of Hematology
Sylvester Comprehensive Cancer Center
University of Miami Health System
Miami, FL

Disclosures: Consultant: Bristol Myers Squibb/Celgene Corporation, Takeda Oncology /Millenium Pharmaceuticals, Novartis Pharmaceuticals Corporation, Merck & Co.

Amy DeZern, MD, MHS
Amy DeZern, MD, MHS
Director, Bone Marrow Failure and MDS Program
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Disclosures: Consultant: AbbVie, Novartis Pharmaceuticals Corporation, Bristol Myers Squibb.

Rami S. Komrokji, MD
Rami S. Komrokji, MD
Senior Member
Section Head, Leukemia and MDS
Vice Chair, Department of Malignant Hematology
Moffitt Cancer Center
Professor of Medicine and Oncologic Sciences
University of South Florida
Tampa, FL

Disclosures: Consultant: AbbVie, Agios Pharmaceuticals, Bristol Myers Squibb/Celgene Corporation, Geron Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation; Speakers Bureau: AbbVie, Agios Pharmaceuticals, Bristol Myers Squibb/Celgene Corporation, Jazz Pharmaceuticals.

Bhumika Patel, MD
Bhumika Patel, MD
Member, Hematopoietic and Immune Cancer Biology Program
Case Comprehensive Cancer Center
Case Western Reserve University
Cleveland Clinic
Cleveland, OH

Disclosures: Speakers Bureau: Alexion Pharmaceuticals, Apellis Pharmaceuticals.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.


Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
    123
45678910
11121314151617
18192021222324
25262728293031
Filter By